As pharmacologic agents encompassing angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), RASi exhibit the clinically validated capacity to decelerate CKD progression. This evidence concerns the gene ACE and chronic kidney disease.